425: Curaleaf Offers Aurora Shareholders 45% Premium

Curaleaf Holdings, Inc. has published a brochure urging Aurora shareholders to tender their shares, offering a 45% premium and a stake in a combined global cannabis leader.

Summary

• Curaleaf Holdings, Inc. is making an offer to acquire Aurora, encouraging Aurora shareholders to tender their shares.
• The offer includes a 45% premium over the 30-day volume-weighted average price (VWAP) of Aurora's shares as of August 10, 2026.
• Aurora shareholders would receive 0.3463 Curaleaf shares and US$0.75 cash per Aurora share, implying an offer price of US$4.00 per share.
• Curaleaf highlights that the combined entity would be the world's leading cannabis company with operations in 17 countries, over US$1.5 billion in last-twelve-month revenue, and nearly US$350 million in adjusted EBITDA.
• The combination is expected to yield at least US$40 million in annual cost synergies.
• Curaleaf contrasts this offer with Aurora's standalone plan, which it describes as a multi-year turnaround with declining revenue and adjusted EBITDA, and negative operating cash flow.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strongly positive development for Aurora shareholders, as Curaleaf is offering a significant premium and a compelling alternative to Aurora's current turnaround plan.

Positives

• Aurora shareholders are offered a 45% premium on their investment.
• The offer provides immediate value and allows participation in the future upside of a larger, more diversified global cannabis platform.
• The combined company is projected to have over US$1.5 billion in LTM revenue and nearly US$350 million in LTM adjusted EBITDA.
• Expected annual cost synergies of at least US$40 million are anticipated.
• Aurora shareholders would gain exposure to Curaleaf's leading U.S. platform and potential benefits from regulatory reform.
• Curaleaf's share price increased approximately 50% in the first six months of 2026, contrasting with Aurora's decline.

Negatives

• Aurora's management has reportedly refused to engage constructively with Curaleaf's offer.
• Aurora's standalone business is described as being in a multi-year turnaround plan with declining revenue and adjusted EBITDA.
• Aurora's net revenue declined 14% and adjusted EBITDA declined 78% over the last four quarters.
• Aurora has experienced negative operating cash flow in two of the last four quarters.
• Aurora's auditors have raised questions about management's inventory controls.
• Aurora's share price has declined significantly (97%) under current CEO Miguel Martin.

Risks

• Aurora's management has not delivered on past performance, with significant declines in revenue and EBITDA.
• The effectiveness of Aurora's multi-year turnaround plan remains uncertain.
• Potential for continued equity dilution for Aurora shareholders if they do not accept the offer.
• The combined entity's success depends on achieving projected synergies and navigating regulatory environments.
• Curaleaf's offer is contingent on a successful tender of Aurora shares.

Future Outlook

Curaleaf anticipates that the combination with Aurora will create the world's leading cannabis company with strong growth prospects, broader geographic diversification, and significant cost synergies. Aurora shareholders are presented with an opportunity to participate in this future upside, contrasting with Aurora's own management-guided lower revenue and adjusted EBITDA projections for the next year.

Management Comments

• "Our Offer to buy Aurora and combine the two businesses delivers immediate value while allowing shareholders to participate in the future upside of the largest, most diversified global cannabis platform."
• "Together, Curaleaf and Aurora would create the global cannabis leader with operations across 17 countries, more than US$1.5 billion of last- twelve-month revenue, nearly US$350 million of adjusted EBITDA and at least US$40 million of expected annual cost synergies."
• "Aurora shareholders would retain exposure to the future of Auroras international business while also gaining exposure to Curaleafs leading U.S. platform and the potential benefits of continued regulatory reform."
• "Aurora has valuable assets. But years of underperformance, dilution, and missed expectations have left shareholders with little to show for them. Curaleaf is offering a 45% premium and greater opportunity ahead."

Industry Context

StockSavvy.ai notes that this unsolicited offer highlights the ongoing consolidation trend within the global cannabis industry, driven by the pursuit of scale, market leadership, and operational efficiencies. Curaleaf's aggressive move suggests a belief in the long-term potential of the sector and a strategic effort to gain a dominant position by acquiring a competitor facing significant operational challenges.

Comparison to Industry Standards

• Curaleaf's offer represents a 12.0x adjusted EBITDA multiple based on CY2026E estimates, which is 68% above the Canadian peer average of 7.1x.
• Curaleaf's share price performance (approx. 50% increase in H1 2026) significantly outperforms Aurora's (approx. 34% decline in H1 2026).
• The combined entity's projected LTM revenue of US$1.5 billion+ and LTM adjusted EBITDA of nearly US$350 million would position it as a leader in the global cannabis market, surpassing many competitors in scale and financial performance.

Stakeholder Impact

• Shareholders: Aurora shareholders are presented with a choice to accept a significant premium or remain with a company undergoing a challenging turnaround. Curaleaf shareholders may benefit from the increased scale and potential synergies of the combined entity.
• Employees: The combination could lead to restructuring and potential job losses due to synergies, but also offers opportunities within a larger, more stable organization.
• Creditors: The financial stability of the combined entity may be improved, potentially benefiting creditors.
• Suppliers: Consolidation could lead to renegotiated terms or reduced supplier numbers.

Next Steps

• Aurora shareholders are encouraged to review the Offer Materials and tender their shares to Curaleaf's offer.
• The offer is subject to the tender of Aurora shares by the deadline of December 1, 2026.
• Curaleaf remains prepared to engage constructively with Aurora's management.

Key Dates

Recommendation

For Aurora shareholders, holding is recommended to await potential further negotiation or to evaluate the final outcome of the tender offer. Accepting the offer provides immediate value, but the long-term potential of the combined entity under Curaleaf's leadership, and the possibility of a higher counter-offer, warrant careful consideration rather than an immediate sell.

Keywords

cannabis acquisition, tender offer, Aurora Cannabis, Curaleaf Holdings, shareholder value, cannabis industry, merger, synergies